<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959945</url>
  </required_header>
  <id_info>
    <org_study_id>PSC08</org_study_id>
    <nct_id>NCT01959945</nct_id>
  </id_info>
  <brief_title>Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)</brief_title>
  <official_title>Evaluation of the Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Quadrivalent Recombinant Influenza Vaccine,Seasonal Formulation) Administered Intramuscularly to Healthy Children and Adolescents Age 6-17 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protein Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protein Sciences Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Flublok was studied previously in children 6 -59 months of age and demonstrated less than
      satisfactory immunogenicity results, especially in the 6-36 month age group. Thus, the
      initial introduction of Flublok Quadrivalent Formulation (RIV4) into the pediatric population
      will evaluate immunogenicity and safety older children and adolescents, aged 6-17. This
      clinical trial is designed to demonstrate safety and non-inferior immunogenicity of Flublok-Q
      in pediatric subjects 6-17 years of age as compared to IIV4. Positive results in this study
      may support further studies in younger children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The U.S. Advisory Committee on Immunization Practices (ACIP) recommends that all people ≥6
      months of age receive influenza vaccine annually. Recommendations for influenza immunization
      of children vary somewhat among countries in the European Union, but immunization of children
      at high risk for complications of influenza infection is recommended by WHO and according to
      criteria in most countries. Currently, the immunization practices are progressing to
      quadrivalent formulations of inactivated influenza vaccines (IIV4) which are approved in the
      US for most of the indicated population. Additionally, live attenuated vaccine (LAIV4) is
      approved in the U.S. for individuals aged 2-49 years and Flublok®(RIV3), a purified trivalent
      recombinant hemagglutinin protein vaccine is approved in the U.S. for adults 18-49 years of
      age. Children are at particular risk of complications of influenza, including the B lineages,
      so expansion of the Flublok indication into the pediatric age group with a quadrivalent
      formulation is warranted.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine.</measure>
    <time_frame>Day 0 up to Day 28 post vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Bruising, Redness, and Swelling; Solicited systemic reactions: Headache, Chills, Fever, Fatigue, Muscle Pain, Joint Pain and Nausea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</measure>
    <time_frame>Day 0 and Day 28 after final vaccination (Cohort B includes 1-Dose subjects at Day 28 and 2-Dose subjects at Day 56)</time_frame>
    <description>Immunogenicity will be evaluated prior to vaccination and at 28 days after vaccination using the hemagglutination inhibition (HAI) technique. For each influenza vaccine strain, pre and post vaccination geometric mean titers (GMTs) and seroprotection and seroconversion will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</measure>
    <time_frame>Day 28 after final vaccination</time_frame>
    <description>Seroconversion is defined as: Either a pre vaccination titer &lt; 10 (1/dil) and a post vaccination titer ≥ 40 (1/dil), or a pre vaccination titer ≥ 10 (1/dil) and a ≥ 4 fold increase in post vaccination titer at Day 28 after the final vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</measure>
    <time_frame>Day 28 after final vaccination</time_frame>
    <description>Seroprotection is defined as: A titer ≥ 40 (l/dil) at pre vaccination and at Day 28 after the final vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Study Group 1, Flublok</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2, Fluarix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 3, Flublok</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 4, Fluarix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flublok® Quadrivalent Influenza Virus Vaccine</intervention_name>
    <description>Intramuscular (Relevant year formulation)</description>
    <arm_group_label>Study Group 1, Flublok</arm_group_label>
    <arm_group_label>Study Group 3, Flublok</arm_group_label>
    <other_name>Recombinant Influenza Vaccine (RIV4)</other_name>
    <other_name>Flublok Influenza Vaccine</other_name>
    <other_name>rHA</other_name>
    <other_name>rHA0</other_name>
    <other_name>Recombinant Hemagglutinin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix Quadrivalent® Influenza Virus Vaccine</intervention_name>
    <description>Intramuscular (Relevant year formulation)</description>
    <arm_group_label>Study Group 2, Fluarix</arm_group_label>
    <arm_group_label>Study Group 4, Fluarix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female age 6-17 years (Cohort A: 6-8 years of age; Cohort B: 9-17 years of
             age)

          2. Female subjects of child-bearing potential (as defined by the onset of menses) must
             agree to avoid becoming pregnant and to use effective method of contraception or
             practice abstinence for at least 28 day prior to the first study vaccine
             administration, until the completion of the study. Female subjects of child-bearing
             potential must have a negative pregnancy test within 24 hours prior to vaccine
             administration.

          3. In good general health, as determined by medical history and targeted physical
             examination, if indicated

        The parent(s) or legal representative(s) of each potential subject must:

          1. Comprehend the study requirements and agree to comply with planned study procedures
             and visits

          2. Provide written consent prior to enrollment and initiation of any study procedures
             Pediatric assent will be obtained in accordance with the Institutional Review
             Board/Independent Ethics Committee determination.

        Exclusion Criteria:

          1. Known allergy to eggs, severe allergy (e.g. anaphylaxis) to other components of either
             vaccine or contraindications to receipt of the comparator IIV4

          2. Immunosuppression as a result of an underlying illness or treatment. Note: Subjects on
             nasal or topical steroids will be allowed

          3. Active neoplastic disease or a history of any malignancy.

          4. History of receiving influenza vaccine within the past 6 months or plans during the
             study to receive influenza vaccine outside of this study.

          5. History of receiving immunoglobulin or other blood product within the 3 months prior
             to enrollment in this study.

          6. Receipt of any non-study licensed vaccines within 2 weeks (for inactivated vaccines)
             or 4 weeks (for live vaccines) prior to enrollment in this study, or plans during the
             study to receive a licensed vaccine within 4 weeks of a study dose [See above for
             influenza vaccines].

          7. Acute or chronic medical condition that, in the opinion of the investigator, would
             render immunization unsafe or would interfere with the evaluation of immune responses

          8. History of severe reactions following immunization.

          9. An acute illness, including a body temperature greater than 100*F, within 3 days prior
             to immunization.

         10. Receipt of an experimental vaccine or medication within 1 month prior to enrollment in
             this study, or expectation of receiving an experimental vaccine, medication, or blood
             product during the study Stage in which the subject will participate.

         11. Developmental delay, neurologic disorder, or seizure disorder requiring ongoing
             medical management (note: history of seizure is not an exclusion criterion).

         12. Any other condition or situation that would, in the opinion of the investigator, place
             the potential subject an unacceptable risk of injury or render the subject unable to
             meet the requirements of the protocol.

         13. History of Guillain-Barré syndrome.

         14. Known pregnancy, positive urine or serum pregnancy test within 24 hours prior to
             planned study vaccination, or breast-feeding.

         15. Concurrent participation in another clinical trial (in active or follow-up phase).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Dunkle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Protein Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maine Research Associates, LLC</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.flublok.com</url>
  </link>
  <link>
    <url>http://www.proteinsciences.com</url>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <results_first_submitted>June 17, 2016</results_first_submitted>
  <results_first_submitted_qc>June 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2016</results_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Hemagglutinins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The randomized population (219 subjects) includes all subjects who were randomized and the safety population (217 subjects) includes all randomized subjects who received any dose of study vaccine and provided any safety. Two (2) randomized subjects did not fit the criteria to be included in the safety population and were excluded from the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group 1, Flublok Cohort A</title>
          <description>Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="P2">
          <title>Study Group 2, Fluarix Cohort A</title>
          <description>Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="P3">
          <title>Study Group 3, Flublok Cohort B</title>
          <description>Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="P4">
          <title>Study Group 4, Fluarix Cohort B</title>
          <description>Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group 1, Flublok Cohort A</title>
          <description>Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="B2">
          <title>Study Group 2, Fluarix Cohort A</title>
          <description>Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="B3">
          <title>Study Group 3, Flublok Cohort B</title>
          <description>Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="B4">
          <title>Study Group 4, Fluarix Cohort B</title>
          <description>Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="217"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>9-17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-8 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine.</title>
        <description>Solicited injection site reactions: Pain, Bruising, Redness, and Swelling; Solicited systemic reactions: Headache, Chills, Fever, Fatigue, Muscle Pain, Joint Pain and Nausea.</description>
        <time_frame>Day 0 up to Day 28 post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1, Flublok Cohort A</title>
            <description>Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 3, Flublok Cohort B</title>
            <description>Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 2, Fluarix Cohort A</title>
            <description>Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O4">
            <title>Study Group 4, Fluarix Cohort B</title>
            <description>Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine.</title>
          <description>Solicited injection site reactions: Pain, Bruising, Redness, and Swelling; Solicited systemic reactions: Headache, Chills, Fever, Fatigue, Muscle Pain, Joint Pain and Nausea.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Solicited Systemic Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Local Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</title>
        <description>Immunogenicity will be evaluated prior to vaccination and at 28 days after vaccination using the hemagglutination inhibition (HAI) technique. For each influenza vaccine strain, pre and post vaccination geometric mean titers (GMTs) and seroprotection and seroconversion will be calculated.</description>
        <time_frame>Day 0 and Day 28 after final vaccination (Cohort B includes 1-Dose subjects at Day 28 and 2-Dose subjects at Day 56)</time_frame>
        <population>The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and ~28 days following completion of immunization (~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1, Flublok Cohort A</title>
            <description>Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2, Fluarix Cohort A</title>
            <description>Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3, Flublok Cohort B</title>
            <description>Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O4">
            <title>Study Group 4, Fluarix Cohort B</title>
            <description>Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</title>
          <description>Immunogenicity will be evaluated prior to vaccination and at 28 days after vaccination using the hemagglutination inhibition (HAI) technique. For each influenza vaccine strain, pre and post vaccination geometric mean titers (GMTs) and seroprotection and seroconversion will be calculated.</description>
          <population>The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and ~28 days following completion of immunization (~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 - A/California/7/2009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.94" lower_limit="38.83" upper_limit="77.73"/>
                    <measurement group_id="O2" value="59.79" lower_limit="43.05" upper_limit="83.02"/>
                    <measurement group_id="O3" value="85.89" lower_limit="44.83" upper_limit="164.57"/>
                    <measurement group_id="O4" value="57.04" lower_limit="31.29" upper_limit="103.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - A/California/7/2009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="914.92" lower_limit="693.4" upper_limit="1207.19"/>
                    <measurement group_id="O2" value="564.23" lower_limit="449.6" upper_limit="708.07"/>
                    <measurement group_id="O3" value="1224.31" lower_limit="749.8" upper_limit="1999.05"/>
                    <measurement group_id="O4" value="695.03" lower_limit="501.5" upper_limit="963.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - A/Texas/50/2012</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.57" lower_limit="140.4" upper_limit="234.83"/>
                    <measurement group_id="O2" value="141.91" lower_limit="108.7" upper_limit="185.25"/>
                    <measurement group_id="O3" value="272.74" lower_limit="181.7" upper_limit="409.37"/>
                    <measurement group_id="O4" value="161.32" lower_limit="113.0" upper_limit="230.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - A/Texas/50/2012</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="852.30" lower_limit="698.1" upper_limit="1040.64"/>
                    <measurement group_id="O2" value="531.36" lower_limit="449.8" upper_limit="627.75"/>
                    <measurement group_id="O3" value="1071.58" lower_limit="776.2" upper_limit="1479.45"/>
                    <measurement group_id="O4" value="629.48" lower_limit="451.4" upper_limit="877.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - B/Massachusetts/2/2012</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.44" lower_limit="16.11" upper_limit="25.94"/>
                    <measurement group_id="O2" value="21.17" lower_limit="16.15" upper_limit="27.75"/>
                    <measurement group_id="O3" value="13.89" lower_limit="9.54" upper_limit="20.23"/>
                    <measurement group_id="O4" value="12.19" lower_limit="8.89" upper_limit="16.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - B/Massachusetts/2/2012</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.02" lower_limit="124.8" upper_limit="207.83"/>
                    <measurement group_id="O2" value="119.96" lower_limit="95.07" upper_limit="151.37"/>
                    <measurement group_id="O3" value="111.14" lower_limit="69.87" upper_limit="176.79"/>
                    <measurement group_id="O4" value="122.90" lower_limit="81.92" upper_limit="184.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 - B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.49" lower_limit="10.17" upper_limit="15.33"/>
                    <measurement group_id="O2" value="10.56" lower_limit="8.62" upper_limit="12.94"/>
                    <measurement group_id="O3" value="11.43" lower_limit="8.32" upper_limit="15.69"/>
                    <measurement group_id="O4" value="9.36" lower_limit="7.05" upper_limit="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 - B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.73" lower_limit="39.73" upper_limit="67.34"/>
                    <measurement group_id="O2" value="59.67" lower_limit="47.30" upper_limit="75.27"/>
                    <measurement group_id="O3" value="73.82" lower_limit="45.05" upper_limit="120.96"/>
                    <measurement group_id="O4" value="60.74" lower_limit="40.35" upper_limit="91.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</title>
        <description>Seroconversion is defined as: Either a pre vaccination titer &lt; 10 (1/dil) and a post vaccination titer ≥ 40 (1/dil), or a pre vaccination titer ≥ 10 (1/dil) and a ≥ 4 fold increase in post vaccination titer at Day 28 after the final vaccination.</description>
        <time_frame>Day 28 after final vaccination</time_frame>
        <population>The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and ~28 days following completion of immunization (~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1, Flublok Cohort A</title>
            <description>Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2, Fluarix Cohort A</title>
            <description>Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3, Flublok Cohort B</title>
            <description>Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O4">
            <title>Study Group 4, Fluarix Cohort B</title>
            <description>Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</title>
          <description>Seroconversion is defined as: Either a pre vaccination titer &lt; 10 (1/dil) and a post vaccination titer ≥ 40 (1/dil), or a pre vaccination titer ≥ 10 (1/dil) and a ≥ 4 fold increase in post vaccination titer at Day 28 after the final vaccination.</description>
          <population>The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and ~28 days following completion of immunization (~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1: A/California/07/2009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="76.8" upper_limit="93.4"/>
                    <measurement group_id="O2" value="68" lower_limit="55.9" upper_limit="77.8"/>
                    <measurement group_id="O3" value="88" lower_limit="69.8" upper_limit="97.6"/>
                    <measurement group_id="O4" value="75" lower_limit="55.1" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: A/Texas/50/2012</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59" lower_limit="46.7" upper_limit="69.9"/>
                    <measurement group_id="O2" value="49" lower_limit="37.8" upper_limit="61.0"/>
                    <measurement group_id="O3" value="54" lower_limit="33.4" upper_limit="73.4"/>
                    <measurement group_id="O4" value="50" lower_limit="30.6" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Massachusetts/2/2012</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="57.6" upper_limit="79.5"/>
                    <measurement group_id="O2" value="61" lower_limit="49.2" upper_limit="72.0"/>
                    <measurement group_id="O3" value="77" lower_limit="56.4" upper_limit="91.0"/>
                    <measurement group_id="O4" value="82" lower_limit="63.1" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="39.4" upper_limit="65.1"/>
                    <measurement group_id="O2" value="67" lower_limit="53.7" upper_limit="78.0"/>
                    <measurement group_id="O3" value="69" lower_limit="48.2" upper_limit="85.7"/>
                    <measurement group_id="O4" value="73" lower_limit="52.2" upper_limit="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</title>
        <description>Seroprotection is defined as: A titer ≥ 40 (l/dil) at pre vaccination and at Day 28 after the final vaccination.</description>
        <time_frame>Day 28 after final vaccination</time_frame>
        <population>The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and ~28 days following completion of immunization (~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1, Flublok Cohort A</title>
            <description>Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2, Fluarix Cohort A</title>
            <description>Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3, Flublok Cohort B</title>
            <description>Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
          <group group_id="O4">
            <title>Study Group 4, Fluarix Cohort B</title>
            <description>Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine</title>
          <description>Seroprotection is defined as: A titer ≥ 40 (l/dil) at pre vaccination and at Day 28 after the final vaccination.</description>
          <population>The evaluable immunogenicity population includes randomized subjects who received the assigned number of doses of study vaccine and have HAI titers available from blood draws taken at baseline and ~28 days following completion of immunization (~Day 56 for 2-dose subjects), which accounts for the discrepancy in Participants Analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1: A/California/07/2009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="90.7" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99" lower_limit="93.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="86.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="87.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2: A/Texas/50/2012</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="95.3" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="86.8" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100" lower_limit="87.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Massachusetts/2/2012</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="81.7" upper_limit="96.2"/>
                    <measurement group_id="O2" value="90" lower_limit="80.6" upper_limit="95.4"/>
                    <measurement group_id="O3" value="85" lower_limit="65.1" upper_limit="95.6"/>
                    <measurement group_id="O4" value="89" lower_limit="71.8" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="65.5" upper_limit="87.3"/>
                    <measurement group_id="O2" value="86" lower_limit="74.6" upper_limit="93.3"/>
                    <measurement group_id="O3" value="85" lower_limit="65.1" upper_limit="95.6"/>
                    <measurement group_id="O4" value="81" lower_limit="60.6" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs collected 28 days after final study immunization and all Serious Adverse Events (SAEs) collected through one (1) year after last study immunization.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Group 1, Flublok Cohort A</title>
          <description>Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="E2">
          <title>Study Group 3, Flublok Cohort B</title>
          <description>Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
Flublok® Quadrivalent Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="E3">
          <title>Study Group 2, Fluarix Cohort A</title>
          <description>Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
        <group group_id="E4">
          <title>Study Group 4, Fluarix Cohort B</title>
          <description>Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
Fluarix Quadrivalent® Influenza Virus Vaccine: Intramuscular (Relevant year formulation)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <description>A 9 year old African American male with a medical history of asthma was hospitalized for one day for treatment of an asthma attack that occurred 5 months after receipt of IIV4 study vaccine. The event was considered not related to study vaccine.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The numbers of subjects available for analysis in Cohort B (age 6-8 years) was fewer than anticipated due to early termination of enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lisa M. Dunkle, M.D., Chief Medical Officer</name_or_title>
      <organization>Protein Sciences Corporation</organization>
      <phone>203-599-6064 ext 153</phone>
      <email>ldunkle@proteinsciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

